Companies /Healthcare

Vivani Medical Inc

NASDAQ: VANI Biotechnology
$1.05
▲ $0.03 (+2.94%) today
Markets closed · 7:31am ET

VANI at a Glance

Valuation
Market cap
$95.0M
Profitability
EPS (TTM)
$-0.33
Price
52-week range
$1 – $2
Street target
$3.83

Headquartered in Alameda, CA Fiscal year ends December NASDAQ: VANI vivani.com

About Vivani Medical

Vivani Medical, Inc. (Nasdaq: VANI), formerly Second Sight Medical Products, is a clinical-stage biopharmaceutical and medical device company with no commercial revenue. It operates two divisions.

- **Biopharm Division:** Uses the proprietary NanoPortal platform to develop miniature, ultra-long-acting subdermal drug implants. The implants are designed for once- or twice-yearly administration, aiming to improve medication adherence and tolerability. They can also be removed when therapy needs to stop. The lead candidate is NPM-139, a semaglutide (GLP-1) implant for chronic weight management, and the company is building a portfolio of GLP-1 implants for obesity and type 2 diabetes. NPM-139 recently reported positive Phase 1 (SLIM-1) top-line data, and a Phase 2 dose-ranging weight maintenance trial is planned for 2027. Novo Nordisk is evaluating NPM-139 under a non-exclusive agreement.
- **Neurostimulation Division:** Conducted through wholly owned subsidiary Cortigent, which develops brain implant neurostimulation devices. Its products include the Orion cortical stimulation system for blindness, which has FDA Breakthrough Device designation. Cortigent is also developing technology for arm and hand motor recovery after stroke. The predecessor company previously marketed the FDA-approved Argus II retinal prosthesis. Cortigent is pending a merger with Nasdaq-listed ClearOne that would make it a standalone public company under the ticker CRGT. Updated

VANI Coverage

Frequently Asked Questions

What does Vivani Medical do?

Vivani Medical, Inc. (Nasdaq: VANI), formerly Second Sight Medical Products, is a clinical-stage biopharmaceutical and medical device company with no commercial revenue.

What is the VANI stock price target?

The Wall Street consensus 12-month price target for VANI is $3.83.